Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

Completed

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.

Key facts

Study ID

NCT00292552

Run by

GlaxoSmithKline

People needed

2747

Starts

2005-12-01

Expected to finish

2010-02-01

Last updated by the study team

2017-03-23

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• COPD Subjects
• A COPD subject will be eligible for inclusion in this study only if all of the following criteria apply:
• Male or female subjects, aged 40-75 years inclusive
• A baseline (post-bronchodilator) FEV1 <80% of predicted normal and a baseline (post-bronchodilator) FEV1/FVC ratio 70%
• Current or ex-smokers with a smoking history of at least 10 pack-years (number of pack years = (number of cigarettes per day / 20) x number of years smoked e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).
• A signed and dated written informed consent is obtained prior to participation
• Able to comply with the requirements of the protocol and be available for study visits over 3 years
• Control Subjects - Current/Ex Smokers
• A control subject will be eligible for inclusion in this study only if all of the following criteria apply:
• Male or female subjects, aged 40-75 years inclusive, who are free from significant disease as determined by history, physical examination and screening investigations
• Baseline (post-bronchodilator) FEV1 >85% of predicted normal. FEV1/FVC ratio >70%
• Current or ex-smokers with a smoking history of at least 10 pack-years (number of pack years = (number of cigarettes per day / 20) x number of years smoked e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).
• A signed and dated written informed consent is obtained prior to participation.
• Able to comply with the requirements of the protocol and be available for study visits over 3 years
• Control Subjects - Non-smokers
• A non-smoking control subject will be eligible for inclusion in this study only if all of the following criteria apply:
• Male or female subjects, aged 40-75 years inclusive, who are free from significant disease as determined by history, physical examination and screening investigations
• Baseline (post-bronchodilator) FEV1 >85% of predicted normal. FEV1/FVC ratio >70%
• Non-smokers with a smoking history of < 1 pack-year (number of pack years = (number of cigarettes per day / 20) x number of years smoked).
• A signed and dated written informed consent is obtained prior to participation.
• Able to comply with the requirements of the protocol and be available for study visits over 3 years

You may not qualify if…

• COPD Subjects
• A COPD subject will not be eligible for inclusion in this study if any of the following criteria apply:
• Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis)
• Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and Lupus)
• Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)
• Having undergone lung surgery (e.g. lung reduction, lung transplant)
• Have cancer or have had cancer in the 5 years prior to study entry
• Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety
• Is enrolled in a long term blinded drug study (subjects in open label studies may be considered and subjects in short blinded studies (approx less than 12 weeks may be considered following consultation with sponsor) or a study where there is significant radiation exposure (e.g.: CT scans)
• Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse
• Have received a blood transfusion in the 4 weeks prior to study start
• Has experienced a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks. All courses of oral corticosteroids and antibiotics must be completed at least 2 weeks before study start
• Is on long term oral corticosteroids (long term is considered use for more than 3 consecutive months)
• Unable to walk
• Subject is a participating investigator, sub-investigator, study co-ordinator, or employee of a participating investigator, or is an immediate family member of the aforementioned.
• Control Subjects
• A control subject will not be eligible for inclusion in this study if any of the following criteria apply:
• Known respiratory disorders, or disorders identified at screening/visit 1 including identification on the first CT scan (e.g.: COPD, asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis)
• Known history of significant inflammatory disease (eg rheumatoid arthritis and Lupus)
• Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)
• Having undergone lung surgery (e.g. lung reduction, lung transplant)
• Have cancer or have had cancer in the 5 years prior to study entry
• Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study
• Is enrolled in a long term blinded drug study (subjects in open label studies may be considered and subjects in short blinded studies (approx less than 12 weeks may be considered following consultation with sponsor) or a study where there is significant radiation exposure (e.g.: CT scans)
• Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse.

Where it is running

• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Rancho Mirage, California, United States
• GSK Investigational Site — Torrance, California, United States
• GSK Investigational Site — Denver, Colorado, United States
• GSK Investigational Site — Hartford, Connecticut, United States
• GSK Investigational Site — New Haven, Connecticut, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Baltimore, Maryland, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Rochester, Minnesota, United States
• GSK Investigational Site — Saint Charles, Missouri, United States
• GSK Investigational Site — Omaha, Nebraska, United States
• GSK Investigational Site — Omaha, Nebraska, United States
• GSK Investigational Site — Lebanon, New Hampshire, United States
• GSK Investigational Site — Pittsburgh, Pennsylvania, United States
• GSK Investigational Site — Providence, Rhode Island, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — San Antonio, Texas, United States
• GSK Investigational Site — Richmond, Virginia, United States
• GSK Investigational Site — Pleven, Bulgaria
• GSK Investigational Site — Sofia, Bulgaria
• GSK Investigational Site — Vancouver, British Columbia, Canada
• GSK Investigational Site — Vancouver, British Columbia, Canada
• GSK Investigational Site — Halifax, Nova Scotia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.